Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Clinical trial NCT05241132 · UNKNOWN

Trial details

NCT number: NCT05241132
Sponsor: Wei Xu
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Cancer of Unknown Primary Bone Cancer Metastatic Tislelizumab Gene Mutation-Related Cancer Immune Evasion, Tumor Chemotherapy Effect

Start date: 2021-11-12
Primary completion: 2023-06-30
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.